Abstract：
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease of unknown origin with limited treatment options and poor prognosis. The encouraging findings from preclinical investigations utilizing mesenchymal stem cells (MSCs) indicated that they could serve as a promising therapeutic alternative for managing chronic lung conditions, such as IPF. The objective of this study was to compare the efficiency of bone marrow-derived MSCs (BM-MSCs) versus prednisolone, the standard anti-inflammatory medication, in rats with bleomycin (BLM)-induced lung fibrosis. Four groups were created: a control group, a BLM group, a prednisolone-treated group, and a BM-MSCs-treated group. To induce lung fibrosis, 5 mg/kg of BLM was administered intratracheally. BLM significantly increased serum levels of pro-inflammatory cytokines and oxidative stress markers. The disturbed lung structure was also revealed by light and transmission electron microscopic studies. Upregulation in the immune expression of alpha-smooth muscle actin, transforming growth factor beta-1, and Bax was demonstrated. Interestingly, all findings significantly regressed on treatment with prednisolone and BM-MSCs. However, treatment with BM-MSCs showed better results than with prednisolone. In conclusion, BM-MSCs could be a promising approach for managing lung fibrosis.
摘要：
特发性肺纤维化（IPF）是一种来源不明的进行性肺部疾病，治疗选择有限，预后不良。来自利用间充质干细胞（MSCs）的临床前研究的令人鼓舞的发现表明，它们可以作为管理慢性肺部疾病的有希望的治疗替代方案。比如IPF。这项研究的目的是比较骨髓来源的MSCs（BM-MSCs）与泼尼松龙的效率，标准的抗炎药,在博来霉素（BLM）诱导的肺纤维化大鼠中。创建了四组：对照组，BLM组，泼尼松龙治疗组，和BM-MSC处理组。诱导肺纤维化，气管内施用5mg/kg的BLM。BLM显著增加促炎细胞因子和氧化应激标志物的血清水平。光和透射电子显微镜研究也揭示了受干扰的肺结构。α-平滑肌肌动蛋白免疫表达上调,转化生长因子β-1和Bax得到证实。有趣的是,所有发现在使用泼尼松龙和BM-MSCs治疗时显著回归。然而,用BM-MSCs治疗的结果优于泼尼松龙。总之,BM-MSC可能是管理肺纤维化的有希望的方法。
